[Research Progress of Expression and Clinical Significant of EZH2 in Hematological Malignancies--Review].

Zhongguo Shi Yan Xue Ye Xue Za Zhi

Department of Hematology, The Second Affiliated Hospital of Air Force Military Medical University, Xi'an 710038, Shanxi Province, China,E-mail: liuli1@ medmail.com.cn.

Published: December 2020

AI Article Synopsis

Article Abstract

Enhancer of zeste homolog 2(EZH2) is a histone methyltransferase which regulate gene expression through epigenetic machinery. The abnormal expression of EZH2 has been described in many cancer types. With in-depth study, it was found that EZH2 is involved in the occurrence and development in many kinds of malignant hematologic disease which may play a dual role of oncogenes and tumor suppressor genes. In recent years, the emergence of EZH2 inhibitors provide a new option for the future treatment of hematological malignancies. In this review, the expression and clinical significance of EZH2 in various of hematological tumors were summarized briefly.

Download full-text PDF

Source
http://dx.doi.org/10.19746/j.cnki.issn.1009-2137.2020.06.050DOI Listing

Publication Analysis

Top Keywords

expression clinical
8
ezh2 hematological
8
ezh2
5
[research progress
4
expression
4
progress expression
4
clinical ezh2
4
hematological malignancies--review]
4
malignancies--review] enhancer
4
enhancer zeste
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!